Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Plasmodium vivax | peptide deformylase, putative | 0.0795 | 1 | 0.5 |
Trypanosoma brucei | Peptide deformylase 2 | 0.0303 | 0.036 | 0.5 |
Mycobacterium tuberculosis | Probable polypeptide deformylase Def (PDF) (formylmethionine deformylase) | 0.0795 | 1 | 0.5 |
Schistosoma mansoni | protein kinase | 0.0631 | 0.6786 | 0.5 |
Toxoplasma gondii | hypothetical protein | 0.0795 | 1 | 0.5 |
Loa Loa (eye worm) | TKL/STKR/TYPE1 protein kinase | 0.063 | 0.6768 | 0.5 |
Echinococcus granulosus | TGF-beta receptor type-1 | 0.0631 | 0.6786 | 1 |
Brugia malayi | bone morphogenetic protein type 1 receptor | 0.063 | 0.6768 | 0.5 |
Treponema pallidum | polypeptide deformylase (def) | 0.0795 | 1 | 0.5 |
Trypanosoma cruzi | Peptide deformylase 2, putative | 0.0303 | 0.036 | 0.5 |
Mycobacterium leprae | PROBABLE POLYPEPTIDE DEFORMYLASE DEF (PDF) (FORMYLMETHIONINE DEFORMYLASE) | 0.0795 | 1 | 0.5 |
Trypanosoma cruzi | polypeptide deformylase-like protein, putative | 0.0303 | 0.036 | 0.5 |
Mycobacterium ulcerans | peptide deformylase | 0.0795 | 1 | 0.5 |
Trypanosoma brucei | Polypeptide deformylase 1 | 0.0303 | 0.036 | 0.5 |
Trypanosoma cruzi | polypeptide deformylase-like protein, putative | 0.0303 | 0.036 | 0.5 |
Plasmodium falciparum | peptide deformylase | 0.0795 | 1 | 0.5 |
Echinococcus multilocularis | TGF beta receptor type 1 | 0.0631 | 0.6786 | 1 |
Leishmania major | polypeptide deformylase-like protein, putative | 0.0303 | 0.036 | 0.5 |
Wolbachia endosymbiont of Brugia malayi | peptide deformylase | 0.0795 | 1 | 0.5 |
Trypanosoma cruzi | Peptide deformylase 2, putative | 0.0303 | 0.036 | 0.5 |
Echinococcus granulosus | TGF beta receptor type 1 | 0.0631 | 0.6786 | 1 |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Homo sapiens | ChEMBL23 | 20845961 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.